Bard’s Oncology Device Success Compensates For Weakened Vascular Sales
This article was originally published in The Gray Sheet
Executive Summary
Bard's Power PICC and Triple Lumen PICC peripherally inserted central catheters helped propel the firm's oncology line during the second quarter
You may also be interested in...
Bard acquires nitinol stent technology
Firm will record a charge of approximately $6 mil. in the first quarter related to its acquisition of certain assets for self-expanding nitinol stent technology from Gainesville, Fla.-based PST, the firm announces Jan. 18. Bard plans to launch a carotid stent in Europe in the second half of 2006 and in the U.S. in 2009 (1"The Gray Sheet" July 25, 2005, p. 22)...
Bard acquires nitinol stent technology
Firm will record a charge of approximately $6 mil. in the first quarter related to its acquisition of certain assets for self-expanding nitinol stent technology from Gainesville, Fla.-based PST, the firm announces Jan. 18. Bard plans to launch a carotid stent in Europe in the second half of 2006 and in the U.S. in 2009 (1"The Gray Sheet" July 25, 2005, p. 22)...
Mid-Sized Bard Delivers Solid Growth In Device Landscape Of Giants, Infants
Bard aims to rely on execution in niche areas where it can comfortably sustain market leadership to deliver sustainable double-digit revenue growth, according to President & CEO Tim Ring